Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride

Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride

Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagen...

Full description

Bibliographic Details
Main Authors:	Tatiana Ivanovna Romantsova, Nadezhda Viktorovna Maksimova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-03-01
Series:	Сахарный диабет
Subjects:	treatment of type 2 diabetes sulfonylureas glimepiride insulin secretion insulin sensitivity
Online Access:	https://www.dia-endojournals.ru/jour/article/view/6017

Similar Items

Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan
by: Mir Iftikhar Bashir, et al.
Published: (2012-01-01)

Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin
by: Resham R Poudel
Published: (2012-01-01)

Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
by: Zimo Zhao, et al.
Published: (2023-07-01)

Effects of Metformin &/or Glimepiride on Resistin Level and Related Biochemical Markers in Type 2 Diabetes Mellitus
by: Hadeel Delman Najim, et al.
Published: (2014-12-01)

Comparison of Hypoglycemic Activity of Berberis Lycium Royle Stem Bark and Glimepiride in Type 2 Diabetes
by: Hina Aslam, Adnan Jehangir, Uzma Naeem
Published: (2015-03-01)

The reversible effects of free fatty acids on sulfonylurea-stimulated insulin secretion are related to the expression and dynamin-mediated endocytosis of KATP channels in pancreatic β cells
by: Chenmin Wei, et al.
Published: (2022-12-01)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
by: Tatiana Ivanovna Romantsova, et al.
Published: (2013-03-01)

Association among insulin receptor substrate1 genetic polymorphism, sulfonylurea therapeutic efficacy, and insulin resistance in patients with type 2 diabetes mellitus
by: Ghada A Omar, et al.
Published: (2021-01-01)

Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01)

Molecules Isolated from Mexican Hypoglycemic Plants: A Review
by: Sonia Marlen Escandón-Rivera, et al.
Published: (2020-09-01)

Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01)

Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety
by: Abdallah M. Beano, et al.
Published: (2017-06-01)

Effect of herbal formulation on glimepiride pharmacokinetics and pharmacodynamics in nicotinamide-streptozotocin-induced diabetic rats
by: Archana K. Thikekar, et al.
Published: (2022-07-01)

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Glibenclamide - profile of efficacy and safety
by: Lyudmila Viktorovna Nedosugova
Published: (2011-09-01)

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-08-01)

Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study
by: Anchit Pareek, et al.
Published: (2023-04-01)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
by: Xie J, et al.
Published: (2019-04-01)

Risk of oncological diseases in patients with diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2009-12-01)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
by: Yeoree Yang, et al.
Published: (2016-10-01)

The hypoglycemic potential of phenolics from functional foods and their mechanisms
by: Oksana Golovinskaia, et al.
Published: (2023-07-01)

Modern antihyperglycemic therapy: safety and efficacy of glimepiride
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2012-06-01)

Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2013-12-01)

Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus
by: Feng Tian, et al.
Published: (2023-02-01)

Age-Related Glucose Intolerance Is Associated with Impaired Insulin Secretion in Community-Dwelling Japanese Adults: The Kumamoto Koshi Study
by: Kazuki Fukuda, et al.
Published: (2025-02-01)

Comparative Evaluation of Vildagliptin-Metformin Versus Glimepiride-Metformin on Inflammatory Markers and Glycemic Control in Type 2 Diabetes Mellitus: A Randomized, Open-Label Study
by: Navreet Kaur, et al.
Published: (2024-07-01)

A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties
by: Xufei Bian, et al.
Published: (2019-10-01)

Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses
by: Darko Stefanovski, et al.
Published: (2022-07-01)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
by: Hae Jin Kim, et al.
Published: (2022-09-01)

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
by: Graziella Bruno, et al.
Published: (2010-09-01)

The role of sulfonylures in the treatment of type 2 diabetes
by: L. A. Sharonova, et al.
Published: (2016-12-01)

Optimization of Potential Nanoemulgels for Boosting Transdermal Glimepiride Delivery and Upgrading Its Anti-Diabetic Activity
by: Marwa H. Abdallah, et al.
Published: (2023-06-01)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
by: Nikolai N. Scherbak, et al.
Published: (2023-09-01)

Analysis of Glimepiride in Human Blood and Urine by Thin Layer Chromatography and UV Spectrophotometry
by: Mareta Mukharbekovna Ibragimova, et al.
Published: (2015-07-01)

Analysis of Glimepiride in Human Blood and Urine by Thin Layer Chromatography and UV Spectrophotometry
by: Mareta Mukharbekovna Ibragimova, et al.
Published: (2015-07-01)

Efek Pemberian Metformin dan Metformin+Glimepiride terhadap Kadar HbA1c pada Pasien Diabetes Mellitus Tipe 2
by: Fitri Apriliany, et al.
Published: (2022-06-01)

Metabolite Signature of Physical Activity and the Risk of Type 2 Diabetes in 7271 Men
by: Susanna Maria Kemppainen, et al.
Published: (2022-01-01)

Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
by: Natalya Vladislavovna Zaytseva, et al.
Published: (2015-06-01)

Visceral fat correlates with insulin secretion and sensitivity independent of BMI and subcutaneous fat in Chinese with type 2 diabetes
by: Haishan Huang, et al.
Published: (2023-02-01)

Formulation and characterization of orodispersible tablet of glimepiride
by: Ahmad AB Yosef Kinani, et al.
Published: (2022-01-01)